About the Company
harpoon therapeutics is a pre-clinical stage biotechnology company co-founded by patrick bauerle, a pioneer in t-cell engagement, and luke evnin (mpm capital) in 2015 to develop and commercialize a novel class of t cell recruiting antibodies engage a patient’s own immune cells to fight cancer and other diseases. the world-class team of protein engineers and immunologists at harpoon have built upon the successful development of the bispecific (“bite™ or bispecific t cell engager”) antibody blincyto® to create a next-generation company dedicated to the development of novel non-antibody biologic therapies with improved efficacy and broad applicability in the treatment of human cancers and other life-altering diseases of the immune system. harpoon’s tri-specific t-cell redirection platform -- tritac™ -- was designed to address the needs of cancer patients not being met by current checkpoint inhibitors, bi-specifics, car-t and other t-cell engaging approaches by improving activity against
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $HARP News
Should You Buy Harpoon Therapeutics, Inc. (HARP) After Golden Cross?
Harpoon Therapeutics, Inc. (HARP) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, HARP's 50-day simple moving average broke out ...
New Suit - Inspection of Books & Records
Harpoon Therapeutics was named in a complaint for inspection of books and records on March 7 in Delaware Court of Chancery in connection with a proposed acquisition by Merck. The suit was brought ...
Merck to pay 118% premium to buy cancer drugmaker Harpoon Therapeutics
Merck & Co. announced Monday an agreement to buy cancer-treatment developer Harpoon Therapeutics Inc. in a deal valued at ...
Merck Completes Acquisition of Harpoon Therapeutics, Inc.
Merck Completes Acquisition of Harpoon Therapeutics, Inc. Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ...
Harpoon Therapeutics Inc. (5HTA.SG) stock forecast and price target
Find the latest Harpoon Therapeutics Inc. 5HTA.SG analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.
Harpoon Therapeutics Inc HARP
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Better Home & Finance Stock (NASDAQ:BETR), Quotes and News Summary
Shares of Harpoon Therapeutics, Inc.(NASDAQ: HARP) rose sharply in pre-market trading. Bloomberg reported that Merck is in advanced talks to buy Harpoon Therapeutics for $23 per share. Avi Kapoor ...
Merck Completes Acquisition of Harpoon Therapeutics, Inc.
today announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP). Harpoon is now a wholly-owned subsidiary of Merck, and Harpoon’s common stock will no ...
Harpoon Therapeutics, Inc. Common Stock (HARP)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past ...
HARP Harpoon Therapeutics, Inc.
The chart has 1 X axis displaying Time. Data ranges from 2020-12-30 21:00:00 to 2032-12-30 21:00:00. The chart has 1 Y axis displaying values. Data ranges from -36.2 to -1.34654.
NASDAQ:HARP (Harpoon Therapeutics, Inc.)
Harpoon Therapeutics Inc is a clinical-stage immunotherapy company. It is engaged in developing a novel class of T cell engagers that harness the power of the body's immune system to treat ...
Merck Completes Acquisition of Harpoon Therapeutics, Inc.
today announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP). Harpoon is now a wholly-owned subsidiary of Merck, and Harpoon’s common stock will no longer be ...
Loading the latest forecasts...